Logo

Merck Licenses Polyplus Transfection Reagent

Oct 24, 2013
Premium

France's Polyplus Transfection announced this week that it has signed a deal to provide its proprietary polyethylenimine, or PEI, transfection reagents to Merck.

Under the deal, Merck acquired the rights to the prior use of PEI for transfection, and Polyplus will supply the drug maker with batches of linear PEI transfection reagent to its sites worldwide.

Financial terms of the arrangement were not disclosed.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Merck
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.